Department of Oncology, Central Finland Central Hospital, Jyväskylä, Finland.
Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, Kuopio, Finland.
Leuk Lymphoma. 2021 Jul;62(7):1639-1647. doi: 10.1080/10428194.2021.1872073. Epub 2021 Feb 5.
Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Finland and Spain including 1020 FL patients to study the influence of sex on disease outcome. The median follow-up duration was 67 months (range 0-226 months). Female patients showed better progression-free survival (PFS) (hazard ratio [HR], 0.720; 95% confidence interval [CI], 0.588-0.881), disease-specific survival (DSS) (HR, 0.653; 95% CI, 0.448-0.951), and overall survival (OS) (HR, 0.653; 95% CI, 0.501-0.853) than male patients. However, there were no significant sex differences in prognosis in patients with early POD. This study strengthens the understanding that male sex is an adverse prognostic factor for FL. However, this difference does not apply to patients with early POD.
关于性别在滤泡性淋巴瘤（FL）中的作用的研究结果存在争议，且疾病早期进展（POD）患者的性别对预后的预测价值仍不清楚。我们收集了芬兰和西班牙 9 家医院的真实数据，共纳入 1020 例 FL 患者，以研究性别对疾病结局的影响。中位随访时间为 67 个月（范围 0-226 个月）。女性患者的无进展生存（PFS）（风险比[HR]，0.720；95%置信区间[CI]，0.588-0.881）、疾病特异性生存（DSS）（HR，0.653；95% CI，0.448-0.951）和总生存（OS）（HR，0.653；95% CI，0.501-0.853）均优于男性患者。然而，在疾病早期进展的患者中，预后并无显著的性别差异。本研究进一步证实了男性性别是 FL 的不良预后因素，但这一差异不适用于疾病早期进展的患者。
